$MLYS News

Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback

Mineralys Therapeutics, Inc. (MLYS) Presents at 35th European Meeting on Hypertension and Cardiovascular Protection - Slideshow

Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026

Mineralys Therapeutics, Inc. (MLYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call Transcript

Mineralys Therapeutics Inc (NASDAQ:MLYS) First Quarter 2026 Results Show Modest Market Reaction to FDA NDA Acceptance

Mineralys Therapeutics Q1 EPS $(0.47), Inline

TD Cowen Initiates Coverage On Mineralys Therapeutics with Buy Rating

Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy?

Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock?

Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors

Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress

Mineralys Therapeutics shares are trading higher after a Form 4 filing showed that a Director purchased 360,000 shares at $23.75 per share on behalf of RA Capital Management.

Mineralys Therapeutics shares are trading higher after a Form 4 filing showed that a Director purchased 360,000 shares at $23.75 per share on behalf of RA Capital Management.

Immunic appoints biopharmaceutical executive Jon Congleton to board

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback?

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics (MLYS) Makes Progress With FDA For Hypertension

Mineralys Therapeutics, Inc. Q4 2025 Earnings Call Summary